I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Several anti-diabetic drugs for type 2 diabetes (T2DM) have underwent cardiovascular (CV) outcome trial (CVOT) since US Food Drug Administration (FDA) and European Medicines Agency mandated this rule in year 2008 and 2012 respectively.\[[@ref1][@ref2]\] There are about 12 of these placebo-controlled trials that have been made available in the last one decade (2008-2018), and several of them are still undergoing whose results are expected in very near future \[[Table 1](#T1){ref-type="table"}\]. Of the 12 trials, 9 were conducted with the drugs which works through incretin-based pathway and 3 trial with the drug which works primarily through sodium-glucose linked transporter-2 receptor (SGLT-2) inhibition in kidney. From the 9 incretin-based trials, 4 trials were conducted with dipeptidyl peptidase-4 inhibitors (DPP-4Is) and other 5 trials with glucagon-like peptide-1 receptor agonist (GLP-1RAs).

###### 

Cardiovascular outcome trials of anti-diabetes drug currently undergoing or completed

  -------------------------------------------------------------------------------------------------------------------------------------
  Class/drugs              Trial eponyms     Comparison        Primary outcome                        Estimated study completion date
  ------------------------ ----------------- ----------------- -------------------------------------- ---------------------------------
  DPP-4 inhibitors                                                                                    

   Saxagliptin             SAVOR-TIMI        Vs. placebo       3P-MACE                                Completed

   Alogliptin              EXAMINE           Vs. placebo       3P-MACE                                Completed

   Sitagliptin             TECOS             Vs. placebo       4P-MACE                                Completed

   Linagliptin             CARMELINA\        Vs. placebo\      3P-MACE\                               Completed\
                           CAROLINA          Vs. glimepiride   3P-MACE                                Completed^@^

   Omarigliptin            OMNEON            Vs. placebo       3P-MACE                                Completed^\#^

  SGLT-2 inhibitors                                                                                   

   Empagliflozin           EMPA-REG          Vs. placebo       3P-MACE                                Completed

   Canagliflozin           CANVAS Program    Vs. placebo       3P-MACE                                Completed

   Dapagliflozin           DECLARE-TIMI      Vs. placebo       3P-MACE/Composite of CV death or HHF   Completed

   Ertugliflozin           VERTIS-CV         Vs. placebo       3P-MACE                                September 2019

   Sotagliflozin           SCORED            Vs. placebo       3P-MACE/Composite of CV death or HHF   March 2022

  GLP-1 receptor agonist                                                                              

   Lixisenatide            ELIXA             Vs. placebo       4P-MACE                                Completed

   Liraglutide             LEADER            Vs. placebo       3P-MACE                                Completed

   Inj. Semaglutide        SUSTAIN-6         Vs. placebo       3P-MACE                                Completed

   Exenatide-LAR           EXSCEL            Vs. placebo       3P-MACE                                Completed

   Albiglutide             HARMONY Outcome   Vs. placebo       3P-MACE                                Completed

   Dulaglutide             REWIND            Vs. placebo       3P-MACE                                Completed^@^

   Oral Semaglutide        PIONEER-6         Vs. placebo       3P-MACE                                Completed^@^

   ITCA 650                FREEDOM           Vs. placebo       3P-MACE                                Completed^@^

  Basal insulin                                                                                       

   Degludec                DEVOTE            Vs. glargine      3P-MACE                                Completed
  -------------------------------------------------------------------------------------------------------------------------------------

^@^Full results yet to be published, ^\#^Early terminated study, CV death: cardiovascular death, 3P-MACE: 3-point composite of major cardiac adverse events (CV death, non-fatal myocardial infarction, non-fatal stroke), 4P-MACE: 3P-MACE plus unstable angina, HHF: Heart failure hospitalization

Although, all these CVOTs have been conducted separately with different degree of background CV disease, the patient characteristics are more similar than dissimilar in these trials. Most of these trials have very similar well-defined pre-adjudicated end points, however if any minor differences in ascertainment of the clinical events may exist, that is likely to be minimized by treatment randomization and blinded adjudication process amongst these CVOTs.

About 4 CVOTs that evaluated DPP-4Is on composite of 3-point/4-point MACE (major cardiovascular adverse events) includes saxagliptin in SAVOR-TIMI (Saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus -- Thrombolysis in myocardial infarction), alogliptin in EXAMINE (Examination of cardiovascular outcomes with alogliptin versus standard of care), sitagliptin in TECOS (Trial evaluating cardiovascular outcomes with sitagliptin) and linagliptin in CARMELINA (Cardiovascular and renal microvascular outcome study with linagliptin in patients with type 2 diabetes mellitus).\[[@ref3][@ref4][@ref5][@ref6]\] Similarly, 3 CVOT that evaluated SGLT-2 inhibitors (SGLT-2Is) includes empagliflozin in EMPA-REG (Empagliflozin reducing excess glucose, canagliflozin in CANVAS Program (CANagliflozin cardiovascular assessment study) and dapagliflozin in DECLARE-TIMI (Trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events).\[[@ref7][@ref8][@ref9]\] The 5 CVOT that was conducted with GLP-1Rs are lixisenatide in ELIXA (Evaluation of lixisenatide in acute coronary syndrome), liraglutide in LEADER (Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results), semaglutide in SUSTAIN-6 (Evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes), exenatide in EXSCEL (Exenatide study of cardiovascular event lowering trial), and albiglutide in HARMONY outcome (Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease).\[[@ref10][@ref11][@ref12][@ref13][@ref14]\]

All these trials compared DPP-4Is/SGLT-2Is/GLP-1RAs respectively to the placebo at the top of background conventional ant-diabetic drugs in T2DM with high CV risk. The similarity and differences in the patient characteristics in all the 12 CVOTs have been summarized in [Table 2](#T2){ref-type="table"}.

###### 

Similarities and differences in 12 cardiovascular outcome trials of anti-diabetic drugs

  Parameters                       SAVOR- TIMI   EXAMINE   TECOS     CARMELINA   EMPA- REG    CANVAS Program   DECLARE - TIMI           ELIXA     LEADER    SUSTAIN-6   EXSCEL    HARMONY
  -------------------------------- ------------- --------- --------- ----------- ------------ ---------------- ------------------------ --------- --------- ----------- --------- ---------
  *n*                              16,492        5,380     14,735    6,979       7,020        10,142           17,160                   6,068     9,340     3,297       14,752    9,463
  Mean age (year)                  65            61        65.5      66          63.1         63.3             63.9                     60.3      64.3      64.6        63        64
  HbA1C entry criteria (%)         6.5-12        6.5-11    6.5-8     6.5-10      7-10         7-10.5           6.5-12                   5.5-11    ≥ 7       ≥ 7         6.5-10    ≥7
  Diabetes duration (mean, year)   10.3          7.3       11.6      15          \>10 (57%)   13.5             11.0                     9.3       12.8      13.9        12        14
  Mean HbA1C (%)                   8             8         7.2       8           8.1          8.2              8.3                      7.7       8.7       8.7         8.0       8.7
  Mean BMI (Kg/M2)                 31.2          28.7      30.2      31.3        30.6         32               32                       30.2      32.5      32.8        31.8      32
  Current smoker, (%)              NR            14        11        10.2        13           17.8             14.5                     11.7      12.1      NR          NR        16
  Asian (%)                        10.7          20.2      22.3      9.0         19.2         12.7             13.4                     12.7      7.6       8.3         9.9       5
  HTN (%)                          82            83        86        91          94           90               89.4                     75.5      90        92.8        NR        86
  CVD (%)                          78            100       100       57          100          65.6             40.6                     100       81        72.2        73.1      100
  Heart failure (%)                13            28        18        27          10.1         14.4             10                       22.4      17.9      23.6        16.2      20
  eGFR \<60 ml ((%)                16.6          29.1      9.3       62.3        25.9         20.1             7.4                      23.2      21.7      24.1        18.6      23
  Median trial duration (year)     2.1           1.5       3.0       2.2         3.1          2.4              4.2                      2.1       3.8       2.1         3.2       1.6
  Events accrued (*n*)             1,222         621       1690      854         772          1011             1559                     805       1302      254         1744      766
  Primary outcome                  3P-MACE       3P-MACE   4P-MACE   3P-MACE     3P-MACE      3P-MACE          3P-MACE/CV Death + HHF   4P-MACE   3P-MACE   3P-MACE     3P-MACE   3P-MACE

HbA1c: Glycated hemoglobin, BMI: Body mass index, HTN: Hypertension, CVD: Cardiovascular disease, NR: Not reported, 3P-MACE: 3-point major adverse cardiac events (composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke), 4P-MACE: 3P-MACE plus hospitalization due to unstable angina, HHF: Hospitalization due to heart failure

There are few other CVOTs which has been recently published other than the twelve placebo-controlled USFDA-mandated trials discussed above. These includes DEVOTE (Trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events), TOSCA-IT (Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin), ACE (Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance), and IRIS (Pioglitazone after ischemic stroke or transient ischemic attack).\[[@ref15][@ref16][@ref17][@ref18]\] We did not include these four trials in this comparative review as both DEVOTE and TOSCA-IT were active-controlled trial not the placebo-controlled, while ACE trial was conducted in patients with impaired glucose tolerance and IRIS was conducted in non-diabetics.

A[IMS AND]{.smallcaps} O[BJECTIVES]{.smallcaps} {#sec1-2}
===============================================

We systematically searched the database of PubMed and ClinicalTrials.gov from January 1, 2008 to December 31, 2018 using MeSH and specific key words and retrieved all the placebo-controlled CVOT done in T2DM with anti-diabetic drugs, post-2008 USFDA mandate. Specific key words include DPP-4 inhibitors, SGLT-2 inhibitors, GLP-1R agonists, sulfonylureas, pioglitazone, insulin, cardiovascular outcome trials. Subsequently, we pooled the data of different cardiovascular endpoints and made a comparative forest plot using GraphPad software Inc. Prism Version 8, US.

This review is an update to our previous systematic review of 2016, which included 7 CVOTs published at that point of time.\[[@ref19][@ref20]\] Here we have aimed to provide readers a latest ready-reckoner monograph of comparative forest plot on major CV endpoints observed in twelve placebo-controlled CVOT of anti-diabetic drugs (ADD), published in last decade (2008-2018).

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Comparative analysis of MACE outcome in CVOTs {#sec2-1}
---------------------------------------------

While 3P-MACE (CV death, non-fatal myocardial infarction \[MI\], non-fatal stroke) was primary objective in all these CVOTs, sitagliptin in TECOS and lixisenatide in ELIXA kept 4P-MACE (component of 3P-MACE plus hospitalization due to unstable angina) as a primary endpoint.

All the 4 DPP-4Is that underwent CVOT such as saxagliptin, alogliptin, sitagliptin and linagliptin achieved the non-inferiority margin on MACE endpoints against placebo, however, no superiority was observed with either agents in the class. With regards to SGLT-2Is, both empagliflozin in EMPA-REG and canagliflozin in CANVAS Program demonstrated a significant superiority in composite of 3P-MACE against placebo (HR = 0.86, 95% CI 0.74-0.99, *P* = 0.04; HR = 0.86, 95% CI 0.75-0.97, *P* = 0.02; all *P* for superiority). While dapagliflozin in DECLARE-TIMI achieved the non-inferiority, it missed to demonstrate the superiority on 3P-MACE (HR = 0.93, 95% CI 0.84-1.03, *P* = 0.17). Nevertheless, dapagliflozin demonstrated a significant reduction in the composite of CV death or hospitalization due to heart failure (HHF), a prespecified co-primary endpoints (HR = 0.83, 95% CI 0.73-0.95, *P* = 0.005) studied exclusively in DECLARE-TIMI.

Amongst the 5 GLP-1RAs trials, both exendin-backbone-based compound such as lixisenatide and extended-releasing exenatide was found to be non-inferior compared to placebo and could not demonstrate superiority. Extended-releasing exenatide missed the statistical significance by a flicker (HR = 0.91, 95% CI 0.83-1.00, *P* = 0.06). In contrast, all GLP-1-backbone-based compound like liraglutide, semaglutide and albiglutide showed superiority on 3P-MACE, compared to placebo (HR = 0.87, 95% CI 0.78-0.97, *P* = 0.01; HR = 0.74, 95% CI 0.58-0.95, *P* = 0.02; HR = 0.78, 95% CI 0.68-0.90, *P* = 0.0006 respectively; all *P* for superiority). Forest plot in [Figure 1](#F1){ref-type="fig"} depicts the reduction in MACE in all 12 CVOTs.

![MACE outcomes in CVOTs](IJEM-23-175-g001){#F1}

Comparative analysis of CV death in CVOTs {#sec2-2}
-----------------------------------------

None of DPP-4Is demonstrated a significant reduction in CV death in any of the CVOTs when compared to the placebo. Similarly, amongst the GLP-1RAs class, neither lixisenatide, nor semaglutide or albiglutide have shown any significant reduction in the CV death in ELIXA, SUSTAIN-6 and HARMONY outcomes respectively. However, liraglutide have demonstrated a significantly reduction in CV death (HR = 0.78, 95% CI 0.66-0.93, *P* = 0.007 for superiority). In the SGLT-2Is class, only empagliflozin shown significant reduction in CV death (HR = 0.62, 95% CI, 0.49-0.77, *P* \< 0.0001 for superiority) compared to placebo in patient with type 2 diabetes and established CV disease. No significant reduction in CV death was observed with canagliflozin and dapagliflozin in CANVAS and DECLARE-TIMI respectively. Forest plot in [Figure 2](#F2){ref-type="fig"} depicts the reduction in CV death in all 12 CVOTs.

![Cardiovascular death in CVOTs](IJEM-23-175-g002){#F2}

Comparative analysis of non-fatal MI in CVOTs {#sec2-3}
---------------------------------------------

There was no significant reduction in non-fatal MI in any of the twelve CVOTs except HARMONY Outcomes. While albiglutide reduced MI (both fatal and non-fatal) in HARMONY (HR = 0.75, 95% CI 0.61-0.90, *P* = 0.003), trends of nonsignificant increase in non-fatal MI was noticed with linagliptin in CARMELINA (HR = 1.15, 95% CI 0.91-1.45, *P* = 0.23). Forest plot in [Figure 3](#F3){ref-type="fig"} depicts the reduction in non-fatal in all 12 CVOTs.

![Non-fatal myocardial infarction in CVOTs](IJEM-23-175-g003){#F3}

Comparative analysis of nonfatal-stroke in CVOTs {#sec2-4}
------------------------------------------------

EXAMINE, TECOS and CARMELINA demonstrated a neutral outcome on non-fatal stroke with alogliptin, sitagliptin and linagliptin respectively, while saxagliptin had a non-significant trend in increase in stroke (including both fatal and non-fatal) in SAVOR-TIMI, compared to the placebo (HR = 1.11, 95%CI 0.88-1.39, *P* = 0.38). In SGLT-2Is class, both canagliflozin and dapagliflozin shown neutral outcome on stroke in CANVAS Program and DECLARE-TIMI respectively, however, empagliflozin had non-significant trend in increase in stroke in EMPA-REG (HR = 1.24, 95% CI, 0.92-1.67, *P* = 0.16). In an independent analysis of FDA, following subgroups of patients that had significantly higher stroke in EMPA-REG which includes\[[@ref21]\]

patients with age \<65 years of age (HR = 1.6, 95% CI 1.03-2.49)patients from Europe (HR = 2.04, 95% CI 1.26-3.29)patients with baseline HbA1c ≥8.5% (HR = 2.13, 95% CI 1.21-3.74)patients treated with insulin (HR = 1.57, 95% CI 1.03-2.41).

With regards to GLP-1RAs class, while liraglutide, extended-releasing exenatide and albiglutide demonstrated neutral outcome in LEADER, EXSCEL and HARMONY outcome respectively, semaglutide showed significant reduction in non-fatal stroke (HR = 0.61, 95% CI, 0.38-0.99, *P* = 0.04) in SUSTAIN-6 against placebo. Lixisenatide showed a non-significant trend in increase in stroke in ELIXA against placebo. Forest plot [Figure 4](#F4){ref-type="fig"} summarizes the non-fatal stroke outcome of all 12 CVOTs.

![Non-fatal stroke in CVOTs](IJEM-23-175-g004){#F4}

Comparative analysis of all-cause mortality in CVOTs {#sec2-5}
----------------------------------------------------

No significant increase or decrease in all-cause mortality was observed with alogliptin, sitagliptin and linagliptin in EXAMINE, TECOS and CARMELINA respectively. Only saxagliptin had non-significant increased trend in SAVOR-TIMI (HR = 1.11, 95% CI 0.96-1.27, *P* = 0.15) against placebo. Amongst the SGLT-2Is class, while empagliflozin significantly reduced all-cause mortality (HR = 0.68, 95% CI, 0.57-0.82, *P* \< 0.0001), canagliflozin and dapagliflozin did not demonstrate any significant reduction. With regards to GLP-1RAs class, while liraglutide and extended-releasing exenatide demonstrated a significant reduction in all-cause mortality in LEADER and EXSCEL (HR = 0.85; 95% CI, 0.74-0.97, *P* = 0.02; HR = 0.86, 95% CI 0.77-0.97, *P* = 0.02) respectively, no reduction was observed with lixisenatide, semaglutide and albiglutide in ELIXA, SUSTAIN-6 and HARMONY outcomes respectively. Forest plot in [Figure 5](#F5){ref-type="fig"} depicts the all-cause mortality across all 12 CVOTs.

![All-cause death in CVOTs](IJEM-23-175-g005){#F5}

Comparative analysis of heart failure hospitalization (HHF) in CVOTs {#sec2-6}
--------------------------------------------------------------------

DPP-4 inhibitors have shown a very differential outcome on HHF. While saxagliptin showed a significant increase in HHF (HR = 1.27, 95% CI, 1.07-1.51, *P* = 0.007) in SAVOR-TIMI, alogliptin showed a similar trend of increase in EXAMINE (HR = 1.19, 95% CI, 0.89-1.58, *P* = 0.24). The post-hoc analyses of SAVOR-TIMI and EXAMINE both suggested that a certain subgroups had a significant increase in HHF in patients with a history of heart failure and or renal disease.\[[@ref22][@ref23][@ref24]\] Moreover, another post-hoc analysis of EXAMINE suggested a significant increase in HHF in patients even without any history of prior heart failure (HR = 1.76, 95% CI 1.07-2.90, *P* = 0.026).\[[@ref25]\] These findings could be misleading because HHF was neither a primary nor a secondary objective in EXAMINE and it was post-hoc analysis and could be subjected to the statistical error. Nonetheless, this outcome is in sharp contrast to sitagliptin (TECOS) and linagliptin (CARMELINA) CVOT where no signals of HHF observed. The subsequent exclusive analysis of HF in TECOS and CARMELINA did not find any signals of the heart failure regardless of the subgroups or the method of statistical analysis applied.\[[@ref26][@ref27]\]

In contrast to SAVOR-TIMI findings, SGLT-2Is class have shown a consistent reduction in HHF. Empagliflozin, canagliflozin and dapagliflozin reduced HHF significantly in EMPA-REG (HR = 0.65, 95% CI, 0.50-0.85, *P* = 0.002), CANVAS program (HR = 0.67, 95% CI 0.52-0.87, *P* not reported) and DECLARE-TIMI (HR = 0.73, 95% CI 0.61-0.88, *P* not reported), respectively. With regards to GLP-1RAs, none of them have shown any harm or benefit except semaglutide in SUTAIN-6 which had non-significant trend in increase in HHF (HR = 1.11, 95% CI 0.77-1.61, *P* = 0.57). No increased signals of HHF with liraglutide in LEADER was more encouraging as previous two trials conducted in patients with heart failure had somewhat discordant noise. FIGHT (Functional impact of GLP-1 for heart failure treatment in patient with advanced heart failure) study (*N* = 300) conducted with liraglutide (Median left ventricular ejection fraction of 25%) had a nonsignificant trend of increase in HHF (HR = 1.30, 95% CI 0.89-1.88, *P* = 0.17) and death (HR = 1.10, 95% CI, 0.57-2.14, *P* = 0.78).\[[@ref28]\] Another study LIVE (Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus) also found a significant increase in serious adverse cardiac events with liraglutide (12 vs. 3, *P* = 0.04), compared to placebo.\[[@ref29]\] Forest plot in [Figure 6](#F6){ref-type="fig"} summarizes the HHF outcomes in all CVOTs.

![Heart failure hospitalization in CVOTs](IJEM-23-175-g006){#F6}

Comparative safety analysis of CVOTs {#sec2-7}
------------------------------------

No significant increase in pancreatitis was observed with any of these trials of either DPP-4Is or GLP-1RAs when compared to the placebo. However, meta-analysis of pooled data of pancreatitis events from all the 4 CVOTs of DPP-4Is, do find increased signals of pancreatitis with this class versus placebo, although significantly high heterogeneity across these trials may limits this conclusion.\[[@ref30]\] Interestingly, no such signals of increase in pancreatitis observed in the pooled meta-analysis of GLP-1RAs CVOTs. There was a significant increased rate of genital infection and increased trend of diabetic keto-acidosis with all the SGLT-2Is. Surprisingly, some of the newer issues have also emerged from these CVOTs of anti-diabetic drugs, which was not observed during their phase 2/3 developmental program. Canagliflozin had significantly higher lower limb amputation rate (HR = 1.97, 95% CI 1.41-2.75) compared to the placebo in CANVAS program. Similarly, increase trend in fractures (HR = 1.23, 95% CI 0.99-1.52) was also noticed with canagliflozin in CANVAS program. No such increased signals of amputation and fractures were observed during prospective evaluation with dapagliflozin in DECLARE-TIMI and retrospective evaluation with empagliflozin in EMPA-REG. A significant increase in acute gall stone disease (*P* \< 0.001) and acute cholecystitis (*P* = 0.046) was observed with liraglutide in LEADER. A significant increase (HR = 1.76; 95% CI 1.11-2.78, *P* = 0.02) in composite of retinopathy complication was observed with semaglutide in SUSTAIN-6. Liraglutide had similar non-significant increase trend in retinopathy complication (HR = 1.15, 95% CI, 0.87-1.52; *P* = 0.33).

C[ONCLUSION]{.smallcaps}, C[OMMENTARY AND]{.smallcaps} F[UTURE]{.smallcaps} A[HEAD]{.smallcaps} {#sec1-4}
===============================================================================================

Collectively from the available evidence, it can be concluded that saxagliptin, alogliptin, sitagliptin and linagliptin are CV neutral drugs. Unexpected increase in HHF with saxagliptin and possibly alogliptin led USFDA to put an additional label of HHF in April 2016 recommending avoidance of both of these drugs in patients with established CVD and or chronic kidney disease.\[[@ref31]\] Interestingly, scientific statement by American Heart Association (AHA) and European Society of Cardiology (ESC) HF guidelines in 2016 also warned about HHF with the entire class of DPP4Is, despite knowing well that there were no signals of hHF with sitagliptin in TECOS which was published in 2015.\[[@ref32][@ref33]\] Although, this move of AHA and ESC was criticized by a group of authors in Lancet.\[[@ref34]\] We are still unclear whether HHF with saxagliptin is truly molecule specific or due to the statistical noise, because no such signals were observed with either sitagliptin or linagliptin. Mechanistic evaluation of glucose-lowering strategies in patients with heart failure (MEASURE-HF) is a 24 week, double-blind, randomized, multi-centric placebo-controlled study (N = 330) is currently evaluating the effects of saxagliptin and sitagliptin on cardiac dimensions and function (change in left ventricular end diastolic volume \[LVEDV\] index measured by MRI) in patients with type 2 diabetes and heart failure.\[[@ref35]\] This study might enlighten us about differential HHF effect between two DPP-4 inhibitors, once it is completed in 2019.

All 3 SGLT-2Is studied so far have shown a consistent benefit on reducing CV risk, especially the HHF. 3P-MACE reduction with both empagliflozin and canagliflozin is noteworthy. CV death and all-cause death reduction with empagliflozin is unique amongst the SGLT-2Is class but this benefit seems to be extending only to the patients with type 2 diabetes and established CVD (secondary prevention cohort). Benefit in HHF and composite of CV death or HHF observed with dapagliflozin in patients with type 2 diabetes with high CV risk (apparently primary prevention cohort) is another unique finding amongst the SGLT-2Is class. It should however be noted that while the results of HHF outcome with SGLT-2Is are in line with some of the recent mechanistical trials, few trials could not demonstrate significant benefit. EMPA-HEART (N = 97) studied for 6-month in patients with T2DM with established CV disease (6% with chronic HF), found a significantly reduction in left ventricular (LV) mass (△ -3.35; 95% CI -5.9, -0.81; *P* = 0.01) with empagliflozin compared to placebo, indicating reverse remodelling with SGLT-2Is.\[[@ref36]\] This result is exciting but it has a limitation of including a very small number of patients, requiring larger and longer trials to conclusively reproduce similar results. Another small-scale, prospective, observational, pilot study (N = 15) of empagliflozin could not demonstrate any significant improvement in exercise tolerance in patients with T2DM with HF with reduced ejection fraction (HFrEF).\[[@ref37]\] REFORM (Safety and Effectiveness of SGLT-2 Inhibitors in patients with heart failure and diabetes), a double-blind, placebo-controlled, discovery-study (N = 58) conducted with dapagliflozin in patients with T2DM with HFrEF has failed to show any significant benefit compared to placebo, although improvement was observed in subgroups with heart failure with preserved ejection fraction (HFpEF) only.\[[@ref38]\]

Like these, there are many exclusive heart failure trials, which are currently under progress and expected to add evidence to the available literature with regards to HF lowering capabilities of SGLT-2Is in patients with or without diabetes, but with established heart failure (both HF with preserved or reduced ejection fraction, [Table 3](#T3){ref-type="table"}). VERTIS-CV (Ertugliflozin treatment in type 2 diabetes mellitus participants with vascular disease) and SCORED (Effect of sotagliflozin on cardiovascular and renal events in patients with type 2 diabetes and moderate renal impairment who are at cardiovascular risk) are next two CVOT being conducted with ertugliflozin and sotagliflozin respectively, that will also add evidence to the available literature for SGLT-2Is.\[[@ref39][@ref40]\]

###### 

Heart failure trials of SGLT-2 inhibitors currently under progress

  Eponyms               *n*    Duration (Month)   Background disease                                                  Primary objective                                                                                Expected results (year)   ClinicalTrial.gov identifier
  --------------------- ------ ------------------ ------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ ------------------------- ------------------------------
  Empagliflozin                                                                                                                                                                                                                                  
   RECEDE-CHF           34     1.5                T2DM with stable HFrEF on loop diuretics                            Changes in urinary output and sodium                                                             February 2019             NCT03226457
   EMBRACE-HF           60     3                  T2DM with HF (HFrEF or HFpEF, ischemic or non-ischemic)             Impact on pulmonary artery diastolic pressure in patients on CardioMEMs device implanted         June 2019                 NCT03030222
   Empire-HF            189    3                  Patients with HFrEF                                                 Changes in NTproBNP                                                                              October 2019              NCT03198585
   EMPA-VISION          86     3                  Patients with HFrEF/HFpEF                                           Change from baseline to week 12 in PCr/ATP ratio in the resting state measured by 31P MRS        October 2019              NCT03332212
   EMPA-RESPONSE        80     1                  Patients with acute decompensated HF                                Change in dyspnea, weight change, hospital stay, NTproBNP, HF readmission, all-cause mortality   December 2019             NCT03200860
   ELSI                 84     3                  Patients with HFrEF/HFmEF                                           Tissue sodium content assessed by 23Na-MRI                                                       December 2019             NCT03128528
   EMPERIAL-Reduced     300    3                  Patients with HFrEF                                                 Exercise capacity by 6-min walk test                                                             December 2019             NCT03448419
   EMPERIAL-Preserved   300    3                  Patients with HFpEF                                                 Exercise capacity by 6-min walk test                                                             December 2019             NCT03448406
   SUGAR                130    10                 T2DM with HFrEF                                                     LVESVI and LV strain measured by cardiac MRI                                                     February 2020             NCT03485092
   EMMY                 476    6.5                Acute MI with or without T2DM                                       Changes in NTproBNP and EF                                                                       April 2020                NCT03087773
   EMPA Acute HF        56     1                  T2DM with acute heart failure                                       Changes in cardiac output measured by ClearSight system                                          May 2020                  NCT03554200
   ERA-HF               128    2                  Patients with HFrEF                                                 Measuring PVC by ICD/CRTD device                                                                 June 2020                 NCT03271879
   EMPEROR-Reduced      2850   38                 Patients with or without T2DM with HFrEF                            Composite of CV death or hHF                                                                     June 2020                 NCT03057977
   EMPEROR-Preserved    4126   38                 Patients with or without T2DM with HFpEF                            Composite of CV death or hHF                                                                     June 2020                 NCT03057951
   EMPA-TROPISM         80     6                  Patients with HFrEF                                                 LVESV and LVEDV                                                                                  December 2020             NCT03485222
   EMPA                 50     1                  T2DM with stable HF loop diuretics                                  Effect on natriuresis measuring urinary Na at day 36                                             June 2022                 NCT03027960
  Dapagliflozin                                                                                                                                                                                                                                  
   DEFINE-HF            250    3                  T2DM with HFrEF (ischemic or non-ischemic)                          Effect on BNP and NTproBNP, symptoms and quality of life                                         April 2019                NCT02653482
   PRESERVED-HF         320    3                  T2DM or IGT with HFpEF                                              Changes in NTproBNP                                                                              September 2019            NCT03030235
   DAPA-HF              4744   36                 T2DM with HFrEF                                                     Composite of CV death or hHF or urgent HF                                                        December 2019             NCT03036124
   DELIVER              4700   33                 Patients with HFpEF                                                 Composite of CV death or hHF or urgent HF                                                        June 2021                 NCT03619213
  Canagliflozin                                                                                                                                                                                                                                  
   CANDLE               250    6                  Canagliflozin versus glimepiride in T2DM with NYHA Class I/III HF   Changes in NTproBNP                                                                              December 2017             UMIN000017669
  \-                    88     3                  Canagliflozin versus sitagliptin in T2DM with NYHA Class I/III HF   Changes in aerobic exercise capacity                                                             March 2019                NCT02920918
  Ertugliflozin                                                                                                                                                                                                                                  
   ETRU-GLS             120    6                  T2DM with stage B HF                                                Changes in global longitudinal strain                                                            October 2020              NCT03717194
   ERADICATE-HF         36     3                  T2DM with HFrEF or HFpEF                                            Changes in proximal Na^+^ reabsorption                                                           March 2021                NCT03416270
  Sotagliflozin                                                                                                                                                                                                                                  
   SOLOIST-WHF          4000   32                 T2DM with HFrEF                                                     Composite of CV death or hHF                                                                     January 2021              NCT03521934

CV: Cardiovascular, T2DM: Type 2 diabetes mellitus, HF: Heart failure, EF: Ejection fraction, HFrEF: Heart failure with reduced ejection fraction, HFpEF: Heart failure with preserved ejection fraction, HFmEF: Heart failure with moderately reduced ejection fraction, SITA: Sitagliptin, LV: Left ventricular, LVESV: Left ventricular end systolic volume, LVEDV: Left ventricular end diastolic volume, LVESI: Left ventricular end systolic index, Na: Sodium, NYHA: New York heart association

With regards to GLP-1RAs, while lixisenatide and extended-release exenatide are CV neutral; liraglutide, semaglutide and albiglutide has shown a significant CV risk reduction (3P-MACE). Moreover, both liraglutide and extended-release exenatide have shown a significant reduction in all-cause death, while only liraglutide has shown a significant reduction in CV death. Furthermore, semaglutide has shown a significant reduction in non-fatal stroke, while albiglutide has shown a nominally significant reduction in MI.

Finally, we need to exercise some cautions while interpreting these CVOTs results. As because HHF, CV death and all-cause deaths are a pre-specified secondary or exploratory end point or based on post-hoc analysis (EXAMINE), these end-points are not included in the statistical hierarchical testing strategies like primary outcomes of 3P/4P-MACE. Thus, any conclusion on these outcomes should be deemed exploratory.
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